1
Paula M Dulski, Robert W Myers, Anne M Gurnett, Sandra J Rattray, Dennis M Schmatz: Histone deacetylase as target for antiprotozoal agents. Merck & Co, Shu M Lee, David L Rose, May 30, 2000: US06068987 (43 worldwide citation)

Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.


2
Helene Perrier, Yongxin Han, Christopher Bayly, Dwight Mac Donald, Andre Giroux, Robert N Young: Aryl furan derivatives as PDE IV inhibitors. Merck & Co, Shu M Lee, David L Rose, February 1, 2000: US06020339 (38 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical ...


3
Christopher Richard Moyes, Michael Rowley: Phenylindole derivatives as 5-ht2a receptor ligands. Merck Sharp & Dohme, J Eric Thies, Shu M Lee, Melvin Winokur, November 12, 2002: US06479480 (33 worldwide citation)

Compounds according to Formula (I) or a salt thereof are selective antagonists of the human 5-HT2A receptor useful for treatment of adverse conditions of the central nervous system:


4
Richard Friesen, Yvbes Ducharme, Daniel Dube, Yves Girard, Richard Frenette, Chun Li, Marc Blouin, Nathalie Chauret, Laird Trimble: PDE IV inhibiting compounds, compositions and methods of treatment. Merck Frosst Canada & Co, Shu M Lee, David L Rose, March 20, 2001: US06204275 (28 worldwide citation)

The invention encompasses compounds of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV).


5
Paula M Dulski, Robert W Myers, Anne M Gumett, Sandra J Rattray, Dennis M Schmatz: Histone deacetylase as target for antiprotozoal agents. Merck & Co, Shu M Lee, David L Rose, August 29, 2000: US06110697 (25 worldwide citation)

Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.


6
Richard Frenette, Yves Ducharme, Sylvie Prescott: Heterosubstituted pyridine derivatives as PDE 4 inhibitors. Merck Frosst Canada & Co, Shu M Lee, David L Rose, November 13, 2001: US06316472 (21 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4).


7
Helmut Kropp, Daniel Farrington, Jeffrey Clark, Ronald Ratcliffe, Robert Wilkening: 9a-azalides as veterinary antimicrobial agents. Merck & Co, Shu M Lee, David L Rose, January 15, 2002: US06339063 (21 worldwide citation)

9a-Azalides, and pharmaceutical compositions containing them, are useful in the treatment and prevention of bacterial respiratory and enteric infections in livestock animals, particularly in cattle and swine.


8
Hans Ulrich Demuth, Jorn Schmidt, Torsten Hoffmann, Konrad Glund: Compounds of unstable DP IV-inhibitors. Prosidion, Shu M Lee, May 30, 2006: US07053055 (19 worldwide citation)

Novel compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabet ...


9
Nicholas D Cosford, Jean Michel Vernier: Substituted pyridines useful as modulators of acetylcholine receptors. Merck & Co, Shu M Lee, David L Rose, February 27, 2001: US06194581 (17 worldwide citation)

In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antag ...


10
James B Williams, Rey T Chern: Long acting injectable formulations containing hydrogenated caster oil. Merck & Co, Merial, Shu M Lee, Mollie M Yang, David L Rose, January 16, 2001: US06174540 (16 worldwide citation)

Long-acting injectable formulations are formed from a) a therapeutic agent selected from insecticides, acaricides, parasiticides, growth enhancers or oil-soluble NSAIDs, b) hydrogenated castor oil, and c) a hydrophobic carrier comprising i) triacetin, benzyl benzoate, ethyl oleate, or a combination ...